Sensus Healthcare landed Health Canada approval for its SRT-100, a therapy device designed to non-surgically treat skin cancer in hospitals and private practice settings.
The SRT-100 system features the company’s SharpBeam characteristics, treating targeted lesions while leaving surrounding healthy tissue intact. The device treats non-melanoma skin cancer, providing virtually pain-free treatment according to the press release.
"We consider Canada as one of the foremost authorities in providing cost effective technologies and we are delighted to have the SRT-100 considered as a viable choice," president & CEO Joe Sardano said in prepared remarks. "We are looking forward to working with Canada’s healthcare professionals."
The SRT-100 system is manufactured in the U.S. and has received FDA clearance as well as CE Mark approval.
On June 4-5, DeviceTalks is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring, bringing you the best and brightest minds in the industry.
Heidi Dohse: Sr. Program Manager, Healthcare, Google, Founder, Tour de Heart Foundation, Acessa Health Inc. Michael J. Pederson: Senior Vice President, Cardiac Arrhythmias and Heart Failure Division, Abbott Hon. Melvin Carter: Mayor, Saint Paul Tim Philips: Compliance Officer, FDA’s Office of Medical Device and Radiological Health Operations Dr. Myriam J. Curet, MD, FACS: Chief Medical Officer, Intuitive Surgical
Take a look at our incredible line up of speakers and join us now.
Use the code "KEYNOTE" to save 15% on the cost of registration.